Ian Krop
Deputy Director, Clinical Affairs, Yale Cancer Center · Yale Cancer Center
Credentials: · · · · ·
History
- Present
Yale Cancer Center
- Present
Yale Cancer Center
Present
Research
Trastuzumab emtansine for HER2-positive advanced breast cancer
New England Journal of Medicine · 2012 · 2,970 citations
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
New England Journal of Medicine · 2020 · 1,630 citations
CDK4/6 inhibition triggers anti-tumour immunity
Nature · 2017 · 1,227 citations
122 papers
61 papers · 1 as a fellow
58 papers
- AW
40 papers
32 papers
29 papers
28 papers
23 papers
Grants
- 1997–2029
- 2013–2025
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
National Cancer Institute · P50
Project lead · $1.7M · Dana-Farber Cancer Inst
- 2002–2003
Characterization of HIN1 Putative Tumor Suppressor
National Cancer Institute · F32
Contact PI · $61.2K · Dana-Farber Cancer Inst
Clinical trials
- 2010–2018
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
- 2007–2012
Principal investigator · Completed · Phase 2
Ian E. Krop, MD, PhD
- 2004
Capecitabine in Women With Operable Breast Cancer
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute